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Background: Several studies have reported success in the use of venous homografts for arteriovenous access and for arterial
bypass in infected fields. On the basis of these reports and in an effort to prevent the loss of vascular access to infection,
we performed arteriovenous graft placement with cryopreserved femoral vein in patients at high risk for graft infection.
This study reviews the results of our experience.
Methods: Of approximately 3100 dialysis access operations performed in a single vascular surgery service between October
1999 and July 2001, 20 patients received arteriovenous access grafts with cryopreserved femoral vein. All patients were
judged to be at high risk for infection of the access on the basis of the presence of active infection at the time of graft
implantation, the location of the graft in the thigh position, or a history of multiple access infections. The grafts were
placed in three locations: thigh (n  14), upper extremity (n  3), and chest wall (n  3).
Results: No early operative deaths or graft thromboses were seen. There were three late deaths: two from cardiac disease
and one from a graft-related complication. Thirteen major graft related complications (65%) occurred in the 20 patients.
There were three generalized graft infections (15%) and eight localized graft infections (40%) at dialysis needle access sites
in 11 patients. Six of the graft infections were associated with graft rupture and frank hemorrhage, resulting in one
patient death from exsanguination. Two grafts (10%) thrombosed, one of which was salvaged after thrombectomy and
revision. These complications occurred between 1 and 14 months after implantation. At a mean follow-up period of 13
months (range, 1 to 17 months), only five of the 20 patients (25%) have a functioning cryopreserved femoral vein
arteriovenous graft.
Conclusion: The use of cryopreserved vein graft for hemodialysis access in patients at high risk for infection is associated
with a high incidence rate of graft infection and rupture, particularly when placed in the thigh position. The routine use
of cryopreserved vein graft in the thigh should be avoided. The in situ replacement of infected polytetrafluoroethylene
arteriovenous grafts with cryopreserved vein should be considered if alternative sites for new access placement are
unavailable. (J Vasc Surg 2002;36:464-8.)
As the demographics of the patient population on
hemodialysis has shifted to older and sicker patients, an
associated increase has been seen in the utilization of arte-
riovenous grafts for hemodialysis access.1 Accompanying
this rise in utilization of arteriovenous grafts has been an
increase in the incidence of graft infection, which occurs at
a rate of approximately 16% overall and between 18% and
35% in the thigh position.2-4 Several innovative techniques
have been described for treating arteriovenous graft infec-
tion while preserving sites for future arteriovenous access
placement.5,6 One method proposed by Matsuura et al7 is
complete graft excision with in situ replacement with cryo-
preserved femoral vein graft. The authors showed favorable
results with the technique in a series of patients with
infected arteriovenous grafts primarily in the arm position.7
Other investigators have reported the successful use of
cryopreserved allografts as conduits for vascular reconstruc-
tion in infected fields.8,9 These encouraging results
prompted us to use cryopreserved femoral vein grafts in a
group of patients undergoing arteriovenous graft place-
ment who were considered at high risk for graft infection.
This study reviews our experience with the cryopreserved
femoral vein for arteriovenous graft placement in this
highly selected patient population.
PATIENTS AND METHODS
From October 1999 to July 2001, 3100 dialysis access
operations were performed by the vascular surgery service
at Greenville Memorial Hospital. During this period, 20
patients underwent arteriovenous graft placement with
cryopreserved femoral vein. In each case, the decision to
use cryopreserved vein was based on a determination by the
attending surgeon of increased risk for subsequent graft
infection. The factors used to determine this risk were
location of the graft in the thigh position (n 14), the need
to place the graft into an infected field (n 4), and a history
of multiple previous arteriovenous graft infections (n 4).
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Two patients had two risk factors for subsequent access
infection (thigh position and active infection).
The grafts were placed in the thigh position in 14 cases,
in the arm in three cases, and on the chest wall (axilloaxillary
loop graft) in three cases. Patient characteristics are shown
in the Table. The ABO type of the implanted graft matched
that of the patient in all cases. All patients received periop-
erative antibiotics. Patients who had grafts implanted di-
rectly into infected tissue received intravenous antibiotics
for at least 2 weeks after surgery.
The cryopreserved femoral vein grafts (CryoLife, Inc,
Kennesaw, Ga) were shipped to the operating room on the
morning of surgery. The technique of graft preparation
outlined by CryoLife, Inc, was strictly followed in all cases.
To ensure quality control, a CryoLife representative was
present during the graft preparation for the initial patient.
All of the thigh and chest wall grafts (n  17) were
constructed in a loop conıguration with two cryopreserved
femoral vein segments sewn end to end before implanta-
tion. The arm grafts (n  3) were constructed in a straight
conıguration with one cryopreserved vein segment. The lot
numbers of the grafts implanted into each patient were
different. No graft was accessed for hemodialysis earlier
than 6 weeks after graft implantation. Data were obtained
from office and hospital charts and our vascular registry.
Patients were generally seen in the office after surgery at 2
weeks and at 6 weeks. After a series of graft-associated
complications were recognized, a graft surveillance pro-
gram was instituted that involved dialysis unit education
and office follow-up every 3 months.
RESULTS
No 30-day operative deaths occurred in the study.
There were three late deaths: two from cardiac disease and
one from exsanguination from graft rupture. Major graft-
related complications occurred in 13 of 20 cases (65%).
Eleven patients (55%) had graft infection develop. The
diagnosis of graft infection was based on clinical findings of
generalized erythema and tenderness over the graft with
associated fever and leukocytosis in three patients, pseudo-
aneurysm of the graft at a needle access site with associated
erythema and tenderness in four patients, and pseudoaneu-
rysm of the graft at a needle access site with skin ulceration
and graft rupture in four patients. Culture results were
obtained in two patients with generalized graft infection
who were found to have perigraft fluid at the time of graft
excision. Culture of the fluid was negative in both patients.
At the time of graft excision, both patients had systemic
signs of sepsis and one patient had a staphylococcal bacte-
remia. In both cases, the patient’s sepsis resolved after graft
excision. Culture results of the wounds or vein grafts in the
other patients with graft infection were not obtained. All of
the graft infections that developed were at sites remote
from the surgical incisions, after apparent healing and after
initiation of hemodialysis. Six of the grafts with localized
infection were excised. Two grafts were salvaged with re-
section of the involved graft segment and restoration of
graft continuity with polytetrafluroethylene graft that was
routed through uninfected tissue.
Infection occurred in 64% (9/14) of the thigh grafts,
33% (1/3) of the arm grafts, and 33% (1/3) of the chest
wall grafts. Cryopreserved femoral vein grafts were used for
in situ replacement of infected polytetrafluroethylene arte-
riovenous grafts in the thigh in two patients, in the arm in
one patient, and in the chest wall in one patient. One of
these grafts placed in the thigh position subsequently be-
came infected and ruptured. The remaining grafts (3/4,
75%) showed no signs of infection, although the graft in the
arm thrombosed at 6 months and was revised. The infec-
tions occurred between 1 month and 14 months after graft
implantation. At the time of diagnosis of cryopreserved vein
graft infection, no patient had a dialysis catheter in place.
Two upper extremity grafts thrombosed at 5 months
and 6 months after implantation. Only one of the grafts
could be salvaged with thrombectomy and revision. Over-
all, at a mean follow-up period of 13 months (range, 1 to 17
months), only five patients (25%) have a functioning cryo-
preserved femoral vein arteriovenous graft.
Graft patency was analyzed with life-table analysis. At
17 months, the primary graft patency rate was 28% and the
secondary patency rate was 31%.
DISCUSSION
Recently, Matsuura et al7 reported results of a series of
44 patients who underwent placement of cryopreserved
femoral vein grafts for hemodialysis access. Although most
grafts were implanted in infected patients, with many grafts
implanted directly into infected tissue, no graft infections
occurred.7 Other investigators have duplicated this success
with the use of cryopreserved vein as an arterial bypass
conduit implanted in situ into infected fields for vascular
reconstruction.8 The prospect of a graft that is resistant to
infection has enormous implications for the patient popu-
lation on hemodialysis. Infection is responsible for substan-
tial cost and morbidity associated with hemodialysis ac-
cess.1,10 Arteriovenous graft infection is even more
devastating in the patient who has limited sites for access
placement because it can mean loss of that site for future
access use. Perhaps those most at risk for graft infection are
patients with arteriovenous grafts placed in the thigh posi-
tion. In a series by Bhandari, Wilkinson, and Sellars,3
infection occurred in 35% of arteriovenous grafts placed in
this position. We recently reported results from our insti-
Patient demographics and complication rate
Patient characteristic Total number Total complication
Male gender 8 6




Peripheral artery disease 6 3
Coronary artery disease 5 2
Obesity 3 3
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tution with polytetrafluoroethylene arteriovenous grafts in
the thigh. We noted an 18% incidence rate of infection,
which is substantially higher than that reported for arm
grafts.4,11
Benedetto et al12 reported that the use of cryopre-
served vein precludes kidney transplantation because of
allosensitization. Also, the cost of cryopreserved vein is five
to 10 times that of polytetrafluoroethylene, depending on
whether one or two segments of the vein are used. We
reasoned that these disadvantages of cryopreserved vein
would be outweighed by the advantage of its resistance to
infection and that the infections prevented would offset the
cost differential between cryopreserved vein and polytetra-
fluoroethylene. Therefore, in an effort to salvage dialysis
access sites despite the presence of infection and to prevent
infection in patients considered to be at high risk for graft
infection, we chose to use cryopreserved femoral vein grafts
for arteriovenous access in a group of 20 selected patients.
Unfortunately, we found a high incidence rate of major
complications associated with cryopreserved femoral vein
arteriovenous grafts. During a 14-month period, a major
complication occurred in 65% of grafts. Most alarming was
the high incidence rate of graft infection and rupture,
which occurred with one associated death. Other investi-
gators’ experiences with cryopreserved vein graft for arte-
riovenous access and arterial reconstruction have suggested
that the patency is similar to that achieved with prosthetic
grafts.7,13 Our patency results may not be a true reflection
of the patency expected from this graft because many of our
grafts were lost early because of infection.
We had strikingly different outcomes with cryopre-
served femoral vein grafts for hemoaccess compared with
those obtained by Matsuura et al.7 The percent of patients
who were at greatest risk for development of subsequent
graft infection, grafts placed directly into infected fields,
were similar between the two studies with nine of 44
(20.5%) in Matsuura et al’s7 study and four of 20 (20%) in
our series. Matsuura et al’s7 indication for use of cryopre-
served vein graft in the remainder of patients in the series
was for localized infection, which was bypassed through
noninfected fields in 11 of 44 patients (25%), for bacter-
emia and sepsis in 14 of 44 patients (31.8%), and for
multiple graft failures in 10 of 44 patients (22.7%). The
indication for usue of cryopreserved femoral vein grafts in
the remainder of patients in our series were for multiple
graft infections in three of 20 patients (15%) and need for
access placement in the thigh position in 14 of 20 patients
(60%). These differences in indication for cryopreserved
vein graft placement resulted in a significantly greater num-
ber of grafts placed in the thigh position in our series.
Perhaps differences in skin flora between the upper extrem-
ity and the thigh render the thigh graft more susceptible to
infection and explain the difference between the results of
the two series.
Three patients in our series died during the period of
review. Two of the deaths were cardiac related, and one
death was from exsanguination from a vein graft rupture.
Our previous study noted a 33% mortality rate in the
patient population in the thigh position. However, none of
these deaths were access related.4 No studies have specifi-
cally addressed the incidence of access-related death.
Our experience is similar to that of Berman et al14 who
reported on a small series of patients who underwent arte-
riovenous access placement with cryopreserved saphenous
vein grafts. In that series, all the grafts (3/3) placed in the
thigh position were lost to pseudoaneurysm and infec-
tion.14
After several graft ruptures occurred in our series, we
instituted a surveillance program of regular follow-up to
identify graft problems early. This involves inspecting the
pseudoaneurysms and the skin integrity over the grafts. The
pseudoaneurysms have been readily apparent on physical
examination, and we have therefore not used duplex ultra-
sonography routinely for surveillance.
Our policy is to revise the graft immediately if a patient
has erythema and tenderness develop over a pseudoaneu-
rysm or if the skin integrity over the pseudoaneurysm is
poor. For most graft revisions, we have used the technique
of segmental bypass with polytetrafluoroethylene and par-
tial graft excision as previously described by our group.5
Revision of cryopreserved vein arteriovenous grafts can be
challenging. The vein is torn easily, and therefore extreme
care must be taken during dissection.
CONCLUSION
The use of cryopreserved femoral vein graft for arterio-
venous access in our experience is associated with an alarm-
ingly high incidence rate of complications, including infec-
tion, graft rupture, and death. Extremely close follow-up is
warranted in those patients who are currently undergoing
dialysis with cryopreserved femoral vein arteriovenous
graft. Complications that arise should be treated early and
aggressively. This study suggests that the routine use of the
cryopreserved femoral vein graft in the thigh position
should be avoided until controlled randomized studies
establish its safety and efficacy compared with polytetraflu-
roethylene grafts. The use of cryopreserved femoral vein
graft for in situ replacement of infected polytetrafluroeth-
ylene arteriovenous grafts should be considered if alterna-
tive sites for new arteriovenous access placement are not
available.
REFERENCES
1. Hirth RA, Turenne MN, Woods JD, Young EW, Port FK, Pauly MV, et
al. Predictors of type of vascular access in hemodialysis patients. JAMA
1996;276:1303-8.
2. Coburn MC, Carney WI. Comparison of basilic vein and polytetrafluo-
roethylene for brachial arteriovenous fistula. J Vasc Surg 1994;20:896-
904.
3. Bhandari S, Wilkinson A, Sellars L. Saphenous vein forearm grafts and
goretex thigh grafts as alternative forms of vascular access. Clin Nephrol
1995;44:325-8.
4. Taylor SM, Eaves GL, Weatherford DA, McAlhany JC, Russell HE,
Langan EM. Results and complications of arteriovenous access dialysis
grafts in the lower extremity: a five-year review. Am Surg 1996;62:188-
91.
5. Schwab DP, Taylor SM, Cull DL, Langan EM, Snyder BA, Sullivan
TM, et al. Isolated arteriovenous dialysis access graft segment infection:
JOURNAL OF VASCULAR SURGERY
September 2002466 Bolton et al
the results of segmental bypass and partial graft excision. Ann Vasc Surg
2000;14:63-6.
6. Bhat DJ, Tellis VA, Kohlberg WI, Driscoll B, Veith FJ. Management of
sepsis involving expanded polytetrafluoroethylene grafts for hemodial-
ysis access. Surgery 1980;87:445-50.
7. Matsuura JH, Johansen KH, Rosenthal D, Clark MD, Clarke KA, Kirby
LB. Cryopreserved femoral vein grafts for difficult hemodialysis access.
Ann Vasc Surg 2000;14:50-5.
8. Fujitani RM, Bassiouny HS, Gewertz BL, Glagov S, Zarins CK. Cryo-
preserved saphenous vein allogenic homografts: an alternative conduit
in lower extremity arterial reconstruction in infected fields. J Vasc Surg
1992;15:519-26.
9. Verhelst R, Lacroix V, Vraux H, Lavigne JP, Vandamme H, Limet R, et
al. Use of cryopreserved arterial homografts for management of infected
prosthetic grafts: a multicentric study. Ann Vasc Surg 2000;14:602-7.
10. The Vascular Access Work Group. NKF-DOQI clinical practice guide-
lines for vascular access. Am J Kidney Dis 1997;30(suppl 3):150-91.
11. Lenz BJ, Veldenz HC, Dennis JW, Khansarinia S, Atteberry LR. A three
year follow-up on standard versus thin wall PTFE grafts for hemodial-
ysis. J Vasc Surg 1998;28:464-70.
12. Benedetto B, Lipkowitz G, Madden R, Kurbanov A, Hull D, Miller M,
et al. Use of cryopreserved cadaveric vein allograft for hemodialysis
access precludes kidney transplantation because of allosensitization. J
Vasc Surg 2001;34:139-42.
13. Harris L, O’Brien-Irr M, Ricotta JJ. Long-term assessment of cryopre-
served vein bypass grafting success. J Vasc Surg 2001;33:528-32.
14. Berman SS, Glickman MH, Hurwitz RL, Strayhorn EC, Fogle MA,
McEnroe CS. Cryopreserved human saphenous vein allografts and their
use in construction of chronic hemodialysis access. In: Sommer BG,
Henry ML, editors. Vascular access for hemodialysis II. Philadelphia:
WL Gore and Associates, and Precept Press; 1991. p. 219-28.
Submitted Jan 21, 2002; accepted Mar 28, 2002.
DISCUSSION
Dr John Matsuura (Atlanta, Ga). I would like to thank the
authors of this presentation for the opportunity to review the
manuscript and President Rosenthal and the society for the oppor-
tunity to make a few comments.
William Bolton, David Cull, and colleagues present a series of
20 renal failure patients undergoing placement of cryopreserved
femoral vein as an AV graft. Unfortunately, the authors encoun-
tered a very high 65% graft complication rate in their series. Two of
the grafts thrombosed, but the analysis of graft thrombosis should
remain separate from the infectious complications and with a
1-year PTFE primary patency rate of 31% to 49%, two graft failures
from thrombosis is not unexpected. However, 55% (11 of 20)
developed infection according to the author’s definition based on
clinical findings alone. One of the weaknesses of this manuscript
was the complete absence of any positive cultures. Three developed
major infections, and eight had puncture site infections with five
grafts developing bleeding that led to one death from exsanguina-
tion.
Since 1996, there have been over 1400 cryopreserved femoral
vein AV grafts placed in the United States. There is a multicenter
prospective database currently being maintained that is tracking
over 200 implants. I looked up the 32 thigh AV grafts from this
series, and the 1-year primary and secondary patency rate is 61%
and 88%, respectively. The graft complications seen in the thigh
locations included two anastomotic leaks requiring revision and
one access site bleed associated with a pseudoaneurysm similar to
the author’s experience. There was also one major bleeding event,
a contained disruption, from recurrent Serratia marcescens infec-
tions. This gives a 13% incidence of serious bleeding complications
in our prospective database, which is much higher than my previ-
ous experience in the upper arm location. From this standpoint, I
would agree with the authors of this paper that the thigh position
does have a higher graft complication rate. I would emphasize the
higher complication rate is related more to location than conduit as
exemplified by Dr Spence Taylor’s own publication in the Ameri-
can Surgeon in 1996 on thigh access from your institution. I do
have a few questions for Dr Bolton.
Based on the three major graft infections seen in this study, do
you feel the virulence of the bacteria should play a role in selecting
cryopreserved femoral vein implantation?
Second, I have discovered that excessive tension and clamp
injury of these allografts leads to a higher incidence of aneurysms.
Do you feel some of the aneurysms in your series may be related to
technical errors?
And finally, one of the most common PTFE AV graft compli-
cations is pseudoaneurysm with bleeding related to excessive re-
current puncture access at the same location in the graft, the
so-called “sweet spot.” The clinical presentation is often a tender
pseudoaneurysm with bleeding related to skin breakdown and
ulceration. Were the eight cases of local infection related to im-
proper access of the same location of the graft, or was it a true
infection? If it was an infection, what was the organism? None of
the cases presented had a positive graft culture result.
Thank you again for a very good presentation. I look forward
to your comments.
Dr William D. Bolton. Thank you Dr Matsuura for your
comments and questions.
Regarding your first question on the role of bacterial virulence
on infection of cryopreserved femoral vein grafts, we can only
speculate since the diagnosis of infection in our series was based
upon clinical findings rather than culture results. Our disappoint-
ing results with cryopreserved femoral vein are quite different from
the favorable results you recently reported. One explanation for the
difference is that the majority of grafts in our series were placed in
the thigh whereas most of the grafts in your series were in the arm.
We surmise that a difference in skin flora between the arm and the
thigh renders grafts placed in the thigh position more susceptible
to infection.
You asked if clamp injury or tension at the anastomosis is a
possible explanation for the aneurysms seen in our series. The
handling characteristics of cryopreserved femoral vein are markedly
different from that of other graft materials. It is obviously impera-
tive then that the graft is handled gently during implantation
because it does not have the wall strength of other graft materials.
Seventeen of the 20 grafts in our study were comprised of two vein
segments in order to allow for a tension-free positioning. To
prevent disruption of the anastomosis and injury to the vein, great
care was taken in tunneling so that there would be no tension or
damage to the graft. We did place a clamp on the graft near the
anastomosis after the initial anastomosis had been completed. The
pseudoaneurysms, which occurred, were at needle stick sites, not
near the anastomosis; therefore, we do not believe these were
related to technical errors of graft insertion.
Finally, you asked if these complications were related to exces-
sive recurrent puncture sites at the same location of the graft. The
cryopreserved femoral vein is a large graft usually measuring over
10 mm in diameter. The majority of grafts in our series were placed
in a loop conıguration using two vein segments. This provided a
larger graft area such that the dialysis nurse should have little
difficulty in finding multiple sites to access these grafts. The fact
that the graft complications occurred in eight different dialysis
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units in our community also leads us to believe that these were not
due to improper sticks.
Thank you.
Dr Charles Kiell (Hickor, NC). I have had experience, a
short experience, with using the saphenous vein as a conduit for
lower extremity reconstruction when there was no usable alterna-
tive and amputation was the only option. My experience somewhat
mirrored yours in the fact that I had two cases of rupture, both in
multiple redo patients at the proximal end of the graft, and in
neither case was the rupture at the site of the anastomosis but was
at a small area of necrosis within the vein graft. One occasion led to
the patient’s death while at home. In both instances, I was able to
examine the graft. The second one I was able to see at the time of
reexploration, and in both, there was a very small pin hole leak that
any other time you would have expected the leak to stop sponta-
neously and in both cases the graft had virtually not incorporated at
all into the adjacent tissues. The reason why I bring it up to convey
the experience is to me this said something about the graft behav-
ior of how it incorporates to adjacent living tissue and, because the
bleeding occurred from very small areas, how it behaves as a site for
normal coagulation and thrombosis to occur that normally one
would have expected this to have sealed off spontaneously.
Dr Alan Lumsden (Houston, Tex). Let me put this in
perspective. This is not a first-line AV access graft. This is not the
graft you use in the easy case. It is a graft that is considered only in
situations where the site is infected or you are on your last legs or
you have multiple thromboses of a PTFE graft. So you cannot
really compare the complication rate with de novo PTFE grafts.
The second issue is that the way that this is approved since it is
a tissue, this comes to clinical use in a very different way from PTFE
grafts, which go the device route. Cryovein has not been tested
through multicenter randomized trials as it probably should be, so
it is not surprising to hear some of these complications.
I have used this graft. I have not seen the same complications
you have, but no question they get pseudoaneurysms. Technically,
they are very difficult to revise because they are very thin, they are
very stuck, and it is an extraordinarily difficult procedure to try and
revise a pseudoaneurysm.
Having said that, I have never put one in the thigh and the
reason for that is because the grafts are short. It is difficult to make
a loop graft with a cryopreserved femoral vein graft unless you are
going to sew two of them together. That makes it very expensive,
and it also puts another anastomosis in there and makes it difficult
to tunnel. You have to be careful in tunneling that you do not
disrupt the anastomoses, and I wonder if any of the complications
were related to the fact that you perhaps were having to sew more
than one segment of these together.
Dr Bolton. None of the complications occurred at an anasto-
mosis. When placing a graft, which utilized two vein segments, we
positioned the counterincision so that it would be over the vein-vein
anastomosis. This was done to ensure that the anastomosis could be
inspected after flow was established in the graft. As I mentioned
earlier, the graft must be handled gently particularly during tunneling.
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